FDA issues black box warning for eczema treatments

Share this article:

The FDA slapped "black box" labeling on Novartis' Elidel and Fujisawa Healthcare's Protopic eczema treatments, warning of the potential risk of cancer the longer the products are used.
The actions follow recommendations made by the FDA's pediatric advisory committee during a meeting in February that reviewed the findings of cancer in three different animal species in tests involving the drugs. The data showed the risk of cancer increased as the amount of the drug given was increased. The data also included a small number of reports of cancers in children and adults treated with Elidel or Protopic.
The FDA said yesterday that the manufacturers of the products have agreed to conduct research to determine whether there is an actual risk of cancer in humans, and, if so, its extent. The agency has also asked physicians to weigh the risks and benefits when prescribing the drugs and not to prescribe the drugs for long periods of time or to children or those with a compromised immune system.
Novartis and Fujisawa have been required to report on any cancers seen among Elidel and Protopic users. There have been 29 reports of cancer, including about a dozen of skin cancer and lymphoma.
"We believe a recommendation to add a black-box warning is unsubstantiated by clinical evidence and experience in more than five million patients world-wide," Novartis said in a Wall Street Journal report.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies